Camouflaging Nanoparticles for Ratiometric Delivery of Therapeutic Combinations
Source abstract
Abstract
Combination therapy is a common clinical practice in the management of malignancies. Synergistic therapeutic outcomes are achieved only when tumor cells are exposed to drugs in an optimal ratio and sequence; therefore, carriers coencapsulating multiple drugs are widely pursued for their coordinated delivery. However, it is challenging to coload drugs with different physicochemical properties in a single carrier with specific ratios. It is not even beneficial to load them in one carrier if they need to be released at different times. We propose to load drugs into chemically compatible carriers separately, equalize different carriers by a simple, rapid, and versatile camouflage technique based on natural polyphenol tannic acid (TA), and administer them in desirable ratios and sequences. To demonstrate this potential, different nanoparticles (NPs) with different charges and material basis, such as polymeric (carboxyl-terminated or amine-terminated cationic polystyrene NPs or poly(lactic- co-glycolic acid (PLGA) NPs), inorganic (mesoporous silica NPs (MSNs)), and liposomal NPs, are camouflaged with TA layers and further modified with folate-conjugated polyethylene glycol to aid in the delivery to tumors. The camouflaged NPs show similar physicochemical properties and interactions with KB cells despite the difference in core platforms, and their mixtures interact with common cell targets in a ratiometric manner. In KB-tumor-bearing mice, the camouflaged PLGA NPs and MSNs show near-perfect colocalization in tumors. These results support that TA helps equalize different NPs with high versatility and enables their ratiometric delivery to common targets. This approach can relieve technical challenges in ratiometric codelivery or sequential delivery of therapeutic agents with distinct physicochemical properties.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907, United States
Department of Pharmaceutics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana 47907, United States
Funding
National Cancer Institute · National Institute of Biomedical Imaging and Bioengineering · China Scholarship Council
References (49)
Show source-provided references
1. 10.1080/17425247.2016.121846410.1080/17425247.2016.1218464 ↗
2. 10.1016/j.addr.2017.06.00310.1016/j.addr.2017.06.003 ↗
3. 10.1016/j.addr.2015.10.02210.1016/j.addr.2015.10.022 ↗
4. 10.6092/1590-8577/202810.6092/1590-8577/2028 ↗
5. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
6. 10.1016/j.addr.2015.10.01410.1016/j.addr.2015.10.014 ↗
7. 10.1080/17425247.2016.120558310.1080/17425247.2016.1205583 ↗
8. 10.1016/j.addr.2017.06.00410.1016/j.addr.2017.06.004 ↗
9. 10.1038/nature2550110.1038/nature25501 ↗
10. 10.1126/science.aah504310.1126/science.aah5043 ↗
11. 10.1002/adfm.20140107610.1002/adfm.201401076 ↗
12. 10.1073/pnas.140623311110.1073/pnas.1406233111 ↗
13. 10.1038/ncomms713910.1038/ncomms7139 ↗
14. 10.1073/pnas.101136810710.1073/pnas.1011368107 ↗
15. 10.3109/02652048.2015.101045910.3109/02652048.2015.1010459 ↗
16. 10.1016/j.jconrel.2015.08.02710.1016/j.jconrel.2015.08.027 ↗
17. 10.1158/1078-0432.CCR-1131-0310.1158/1078-0432.CCR-1131-03 ↗
18. 10.1038/nnano.2012.23710.1038/nnano.2012.237 ↗
19. 10.1021/ja208433810.1021/ja2084338 ↗
20. 10.1021/acsnano.7b0037610.1021/acsnano.7b00376 ↗
21. 10.1038/nnano.2015.33010.1038/nnano.2015.330 ↗
22. 10.1016/j.biomaterials.2008.08.00410.1016/j.biomaterials.2008.08.004 ↗
23. 10.1021/mp050032z10.1021/mp050032z ↗
24. 10.1021/acsami.7b0690610.1021/acsami.7b06906 ↗
25. 10.1007/s13204-017-0593-810.1007/s13204-017-0593-8 ↗
26. 10.1002/anie.20130492210.1002/anie.201304922 ↗
27. 10.1039/C4CC02961E10.1039/C4CC02961E ↗
28. 10.1126/science.123726510.1126/science.1237265 ↗
29. 10.1021/cm403903m10.1021/cm403903m ↗
30. 10.1021/acs.iecr.5b0373510.1021/acs.iecr.5b03735 ↗
31. 10.1039/C6NR00600K10.1039/C6NR00600K ↗
32. 10.1021/acsbiomaterials.6b0049710.1021/acsbiomaterials.6b00497 ↗
33. 10.1002/adfm.20140399210.1002/adfm.201403992 ↗
34. U.S. Food and Drug Administration. New Drug Application (NDA): 011208.
35. 10.1038/s41551-018-0227-910.1038/s41551-018-0227-9 ↗
36. 10.1002/admi.20150029810.1002/admi.201500298 ↗
37. 10.2115/fiber.37.6_T24110.2115/fiber.37.6_T241 ↗
38. 10.1021/acs.molpharmaceut.7b0005010.1021/acs.molpharmaceut.7b00050 ↗
39. 10.3109/1061186X.2015.105482910.3109/1061186X.2015.1054829 ↗
40. 10.1021/nn405809c10.1021/nn405809c ↗
41. 10.1016/S0006-3495(94)80988-910.1016/S0006-3495(94)80988-9 ↗
42. 10.1016/S0378-5173(01)00676-710.1016/S0378-5173(01)00676-7 ↗
43. 10.1021/nl801596a10.1021/nl801596a ↗
44. Juweid M. · Cancer Res. · 1992 · 52 · 5144
45. Graff C. P. · Cancer Res. · 2003 · 63 · 1288
46. 10.1097/CCM.0b013e31824e671310.1097/CCM.0b013e31824e6713 ↗
47. 10.2165/00003495-200969060-0000710.2165/00003495-200969060-00007 ↗
48. 10.1136/jcp.2010.08699110.1136/jcp.2010.086991 ↗
49. 10.1002/admi.20140011310.1002/admi.201400113 ↗